Manhattan Scientifics Inc. (OTCQB: MHTX) announced today that SeeThruEquity, LLC has initiated coverage on the Company. The report is now available for viewing at the following link. “We initiate coverage on Manhattan Scientifics, Inc. (“MSI”) with a price target of $0.14 per share. MSI is focused on technology transfer and the commercialization of transformative technologies in the nanotechnology space. MSI is currently focused on two opportunities, one in nanostructured metals technology through wholly-owned subsidiary Metallicum Inc., and the other in nanoparticle based cancer detection through wholly owned subsidiary Senior Scientific LLC. With one licensing deal already in place, others in negotiation on the metals technology side of the business and commencement of product trials on their cancer detection product slated for 2014, MSI has numerous revenue drivers and catalysts through the 2014-2015 timeframe,” remarked Ajay Tandon, Director of Research at SeeThruEquity, LLC. About SeeThruEquity SeeThruEquity, LLC is an investment research and corporate access firm that produces high quality research reports on smallcap and microcap companies with less than $1 billion in market capitalization. The research is unbiased and not paid-for research. These companies have typically been underserved by the traditional Wall Street analyst establishment. We are unfettered by any ties to investment banking or trading, and distribute our high impact research as an approved contributor on Thomson Reuters One (First Call), CapitalIQ, FactSet, Zacks and StockTwits, as well as to our own audience of investors from our corporate website. We also contribute our financial estimates on companies in our research coverage universe to Thomson Estimates (commonly referred to as consensus or consensus estimates on the Street). For more information, visit http://www.seethruequity.com. The investment opinions expressed are solely those of SeeThruEquity, LLC. SeeThruEquity, LLC has not been compensated for the preparation of the report on the Company by any third party or the Company.Forward-looking statement. This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics Inc. believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.